Try Alerts Free   |   Login
Health Care › LABORATORY ANALYTICAL INSTRUMENTS

SEER Price Correlated With Financials For Seer

Free historical financial statements for Seer Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 7 quarters since 2021. Compare with SEER stock chart to see long term trends.

SEER Stock Compared to Quarterly

SEER Income Statement

Revenue, Net:3955000
Revenue Per Share:0.0632
Cost of Goods & Services Sold:2010000
Gross Profit:1945000
Selling, General & Admin Expense:15447000
Research & Development Expense:11564000
Total Operating Expenses:27011000
Operating Income:-25066000
Net Income:-23980000
Earnings Per Share, Basic:-0.38
Shares Outstanding, Basic Avg:62538983

SEER Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1063000
Net Cash from Operations:-13373000
Net Cash from Operations Per Share:-0.2138
Repurchases/Buybacks Common Stock:0
Net Cash from Financing Activities:169000
Property, Plant & Equipment Purchases:2686000
Net Cash from Investing Activities:2250000
Net Change in Cash & Equivalents:-10954000

SEER Balance Sheet

Cash and Cash Equivalents:436100000
Accounts Receivable, Net:4537000
Inventories:5916000
Total Current Assets:450471000
Property, Plant & Equipment, Net:16084000
Total Assets:500212000
Total Short-Term Liabilities:13616000
Total Liabilities:42444000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
FMR LLC
8,675,843 sh
-83,701 sh
-1%
$67,152
-$11,245
SB Global Advisers Ltd
5,135,383 sh
 
$39,748
Artal Group S.A.
4,750,000 sh
 
$36,765
Vanguard Group Inc
4,427,188 sh
37,054 sh
1%
$34,267
-$5,025
Capital World Investors
4,414,668 sh
1,597,002 sh
57%
$34,170
$8,952
Blackrock Inc.
3,845,928 sh
24,077 sh
1%
$29,768
-$4,438
State Street Corp
1,647,768 sh
175,712 sh
12%
$12,754
-$421
Price T Rowe Associates Inc /Md/
1,496,016 sh
-2,052,320 sh
-58%
$11,580
-$20,178
Maverick Capital Ltd
1,163,792 sh
-1,006,864 sh
-46%
$9,008
-$10,419
Morgan Stanley
830,342 sh
95,625 sh
13%
$6,427
-$149
AJU IB Investment Co., Ltd.
816,375 sh
 
$6,319
Geode Capital Management, LLC
795,206 sh
-2,911 sh
0%
$6,154
-$989
JPMorgan Chase & Co
759,702 sh
-16,206 sh
-2%
$5,881
-$1,064
Northern Trust Corp
418,627 sh
58,133 sh
16%
$3,240
-$2,254
Woodline Partners Lp
342,574 sh
5,129 sh
2%
$2,652
-$368
Mitsubishi Ufj Kokusai Asset Management Co., Ltd.
327,180 sh
-2,334 sh
-1%
$2,532
-$417
Charles Schwab Investment Management Inc
297,104 sh
7,025 sh
2%
$2,300
-$297
1888 Investments, LLC
288,683 sh
92,856 sh
47%
$2,234
$481
Goldman Sachs Group Inc
283,397 sh
10,987 sh
4%
$2,194
-$244
Dimensional Fund Advisors LP
222,316 sh
161,011 sh
263%
$1,721
$1,173
COMPANY PROFILE
ORGANIZATION AND DESCRIPTION OF THE BUSINESS Seer, Inc. (the Company) was incorporated in Delaware on March 16, 2017, and is headquartered in Redwood City, California. In December 2020, the Company formed the wholly-owned subsidiary, Seer Securities Corporation, located in Massachusetts. The Company is a life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease. Since inception, the Company has devoted its efforts principally to research, development and commercialization of its technology and products, recruiting management and technical staff, acquiring operating assets, and raising capital.

The Company is subject to a number of risks, similar to other early-stage life science companies, including, but not limited to, development and commercialization of its products, market acceptance of its products, development by its competitors of new technological innovations, protection of its intellectual property, and raising additional capital.

Public Offering

On February 1, 2021, the Company completed an underwritten public offering of 1,650,000 shares of its Class A common stock at a public offering price of $67.00 per share. The Company received net proceeds of $103.0 million after deducting offering costs, underwriting discounts, and commissions of $7.6 million.

Liquidity

As of March 31, 2022, the Company has incurred significant losses and has had negative cash flows from operations. As of March 31, 2022, the Company had cash, cash equivalents and investments of $471.8 million and an accumulated deficit of $150.2 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of March 31, 2022 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Data imported from Seer Inc. SEC filings. Check original filings before making any investment decision.